Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(4 {(2S)-2 [(tert butoxycarbonyl amino methoxy oxopropyl phenyl methaneseleninic acid is a small molecule organic compound derived from phenylalanine. It features a seleninic acid group attached to the para position of the phenyl ring and is protected by a tert-butoxycarbonyl (Boc) group on the amino terminus. The compound is primarily used in research and has not been developed as a therapeutic agent for any specific disease. Its mechanism of action is not established in clinical or preclinical studies, and it does not have any approved indications or ongoing clinical trials.[1][5][10]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (4-{(2S)-2-[(tert-butoxycarbonyl)amino]-3-methoxy-3-oxopropyl}phenyl)methaneseleninic acid.